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Abstract
Background: The EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative
Efficacy) study was an international, randomized, open-label, assessor-blinded, parallel-group study assessing the
efficacy and tolerability of interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw), and IFN
beta-1a, 30 mcg intramuscularly (im) once weekly (qw), in patients with relapsing-remitting multiple sclerosis
(RRMS). The aim of this analysis was to assess whether reductions in T2 burden of disease (BOD) were greater
for patients receiving IFN beta-1a, 44 mcg sc tiw, than for those treated with IFN beta-1a, 30 mcg im qw, and to
assess the impact of neutralizing antibodies (NAbs).
Methods: A post-hoc analysis was performed on magnetic resonance imaging (MRI) data collected prospectively
from the EVIDENCE study. The analysis included all patients with evaluable T2 MRI scans at the start of dosing
and at week 48, and those who received at least one drug dose (n = 553). Lesions were identified by a radiologist
blinded to treatment codes and the total volume of T2 lesions (BOD) was reported in mm3.
Results: Both median percentage decreases and absolute reduction in BOD were greater in the IFN beta-1a, 44
mcg sc tiw, treatment group. The adjusted mean treatment difference in percentage change in BOD from baseline
to week 48 showed a significant treatment benefit for patients treated with IFN beta-1a, 44 mcg sc tiw, over those
treated with IFN beta-1a, 30 mcg im qw (-4.6%; standard error: 2.6%; p = 0.002). The presence of NAbs reduced
the effect of IFN beta-1a 44, mcg sc tiw, on BOD, but BOD changes were still similar to those seen with IFN beta-
1a, 30 mcg im qw.
Conclusion: Patients with RRMS treated with IFN beta-1a, 44 mcg sc tiw, had greater reduction in T2 BOD after
48 weeks than those treated with IFN beta-1a, 30 mcg im qw, which is consistent with other clinical and MRI
outcome measures in the EVIDENCE study. In patients testing positive for NAbs (NAb+) to IFN beta-1a 44 mcg
sc tiw, changes in BOD were smaller than in NAb negative (NAb-) patients, but similar to those receiving IFN
beta-1a, 30 mcg im qw.
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Interferon (IFN) beta-1a, 44 mcg subcutaneously (sc)
three times weekly (tiw), and IFN beta-1a, 30 mcg intra-
muscularly (im) once weekly (qw), are both licensed for
the treatment of patients with relapsing forms of multiple
sclerosis (MS). These two IFN beta-1a formulations were
compared in the EVIDENCE (EVidence of Interferon
Dose-response: European North American Comparative
Efficacy) study, which was an international, randomized,
open-label, assessor-blinded, parallel-group study to
determine if IFN beta-1a, 44 mcg sc tiw, has greater effi-
cacy on clinical and magnetic resonance imaging (MRI)
outcomes to that of IFN beta-1a, 30 mcg im qw, in
patients with relapsing-remitting MS (RRMS). Patients
treated with IFN beta-1a, 44 mcg sc tiw, had a significantly
higher odds ratio for remaining relapse free at 24 weeks (p
= 0.0005), at 48 weeks (p = 0.009) and over an average of
64 weeks (p = 0.023), compared with patients treated with
IFN beta-1a, 30 mcg im qw [1-3]. In addition, at the same
time points, new activity on MRI was significantly lower
in patients receiving IFN beta-1a, 44 mcg sc tiw, than in
those receiving IFN beta-1a, 30 mcg im qw: reductions
were seen in gadolinium (Gd)-enhancing lesions, T2
active lesions and the proportion of T2 active scans;
increases were seen in the proportion of patients with no
T2 active lesions [1].
Neutralizing antibodies (NAbs) can occur with any IFN
therapy for MS and may impact on efficacy, although
there is debate on the degree of this effect [4]. In the EVI-
DENCE study, 25% of patients receiving IFN beta-1a, 44
mcg sc tiw, and 2% of patients receiving IFN beta-1a, 30
mcg im tiw, had NAb titres greater than 20 neutralizing
units/mL at week 48. There was no apparent effect on clin-
ical efficacy for relapse outcomes, but fewer T2 active
lesions were seen in the IFN beta-1a, 44 mcg sc tiw, NAb-
group compared with the NAb+ group (0.6 versus 1.6
lesions, p = 0.0004).
The aim of this post-hoc analysis of the EVIDENCE data
was to establish whether reductions in T2 burden of dis-
ease (BOD) were also greater for patients treated with IFN
beta-1a, 44 mcg sc tiw, than for those treated with IFN
beta-1a, 30 mcg im qw. Whether NAb status affected treat-
ment outcomes was also assessed.
Methods
Design and objectives
A post-hoc analysis was performed on MRI data that were
collected prospectively from the EVIDENCE study (proto-
col 21125) [3]. This included all randomized patients
who had received at least one dose of the study drug and
had evaluable T2-weighted MRI scans from both before
the start of dosing (week 0) and at week 48. The central
MRI analysis laboratory (USC MS/MRI Research Group)
performed the original activity analysis and remained
blinded for the current analysis throughout. An experi-
enced MRI radiologist evaluated all MRI scans and
remained blinded to treatment. For the T2 BOD analysis,
digital data for the proton density/T2 scans for weeks 0
and 48 were used and the radiologist electronically tagged
all T2 lesions for segmentation. Trained technicians
blinded to study treatment grew each tagged T2 lesion
semi-automatically using proprietary software. The radiol-
ogist performed a final quality-control step before sum-
marizing the results as a total volume (mm3). Combined
unique lesion activity (CUA) analysis was performed pre-
viously up to week 24 and defined as a Gd-enhancing
lesion, new T2 lesion and/or enlarging T2 lesion; this
takes into account that a newly active lesion may appear
on both the MRI following Gd enhancement and on the
T2-weighted MRI, and ensures that it is counted only
once. The primary measure of interest was percentage
change in BOD (mm3) from baseline to week 48. Second-
ary measures of interest were absolute change in BOD
from baseline (week 0) to week 48; percentage and abso-
lute change in BOD from baseline to week 48 when strat-
ified by NAb status (patients with NAb titres ≥ 20
neutralizing units/mL were considered to be NAb+); and
the correlation between changes in BOD from baseline to
week 48 and changes in CUA from baseline to week 24.
NAbs were measured using a cytopathic effect assay [5].
Statistical analyses
Change in BOD from baseline was compared between
treatment groups using an analysis of covariance
(ANCOVA) model with effect of treatment and baseline
BOD as a single covariate. The treatment difference in
means, adjusted for any baseline parameters that were sig-
nificantly different between the groups, and the associated
standard error (SE), were estimated on the raw data from
the ANCOVA model. Treatment comparison p values
were calculated using a similar ANCOVA model on
ranked data. Histograms were constructed by treatment
group to show and evaluate the distribution of percentage
and absolute change in BOD from baseline to week 48.
Differences in percentage change in BOD between
patients receiving IFN beta-1a, 44 mcg sc tiw, and IFN
beta-1a, 30 mcg im qw, were calculated by subtracting cor-
responding adjusted mean changes for each group. A neg-
ative value of the difference in changes indicated that
treatment with IFN beta-1a, 44 mcg sc tiw, resulted in a
larger decrease in BOD than treatment with IFN beta-1a,
30 mcg im qw. Absolute change in BOD was calculated by
subtracting the baseline assessment from the post-treat-
ment assessment. A negative value in either the absolute
change or percentage change indicated suppression in
BOD.Page 2 of 7
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changes in CUA from baseline to week 24 and changes in
BOD from baseline to week 48 was assessed using a Spear-
man's rank correlation analysis.
Results
A total of 677 patients were randomized to treatment in
the EVIDENCE study. Of these, 553 patients met the
inclusion criteria for this analysis (IFN beta-1a, 44 mcg sc
tiw group: n = 279; IFN beta-1a, 30 mcg im qw group: n =
274). Three of 56 centres that participated in the EVI-
DENCE study were only able to provide film (not digital)
MRI data that was suitable for the activity analysis
reported previously [3], but was not suitable for BOD.
This affected both treatment groups equally. The two
treatment groups did not differ significantly in demo-
graphics or baseline lesion characteristics (Table 1).
Median percentage decreases in BOD were greater in the
IFN beta-1a, 44 mcg sc tiw, treatment group (-6.7%; range:
-65 to 431%) compared with the IFN beta-1a, 30 mcg im
qw, treatment group (-0.6%; range: -61 to 197%). The
adjusted mean treatment difference (AMTD) in percent-
age change in BOD from baseline to week 48 showed a
significant treatment benefit for patients treated with IFN
beta-1a, 44 mcg sc tiw, over those treated with IFN beta-
1a, 30 mcg im qw (-4.6%; SE: 2.6%; p = 0.002). Corre-
spondingly, patients in the IFN beta-1a, 44 mcg sc tiw,
treatment group had a greater median absolute change in
BOD (-189.55 mm3; range: -23454 to 56869 mm3) com-
pared with those in the IFN beta-1a, 30 mcg im qw, treat-
ment group (-19.0 mm3; range: -13337 to 10161 mm3;
Figure 1). The distribution of absolute and percentage
changes in BOD from baseline to week 48 are presented
in Figures 2 and 3 and indicate that more patients in the
IFN beta-1a, 44 mcg sc tiw, treatment group had greater
reductions in BOD compared with the IFN beta-1a, 30
mcg im qw, treatment group. In total, 67% of patients
receiving IFN beta-1a, 44 mcg sc tiw, had a stable or
improved BOD compared with 53% of patients receiving
IFN beta-1a, 30 mcg im qw, and 47% of patients in the
IFN beta-1a, 30 mcg im qw, treatment group had
increased BOD between weeks 0 and 48 compared with
33% of patients in the IFN beta-1a, 44 mcg sc tiw, treat-
ment group.
Table 1: Baseline patient demographics and burden of disease.
Interferon beta-1a treatment group
44 mcg sc tiw (n = 279) 30 mcg im qw (n = 274) p value*
Age in years, mean (SD) 38.6 (8.8) 37.7 (8.6) 0.188
Sex, n (%) 0.269
Men 64 (22.9) 74 (27.0)
Women 215 (77.1) 200 (73.0)
Race, n (%) 0.935
White 258 (92.5) 250 (91.2)
Black 12 (4.3) 15 (5.5)
Asian 0 1 (0.4)
Hispanic 5 (1.8) 4 (1.5)
Other 4 (1.4) 4 (1.5)
BOD in mm3, median (range) 5438 (85–135276) 6010 (391–103495) 0.541
*Treatment comparisons with respect to sex and race distributions were performed using a Chi-squared test or a Fisher's Exact test, where 
appropriate. With respect to age and baseline BOD, an analysis of covariance model using ranked data was performed with effects for treatment.
Numbers do not add to 100% due to rounding.
BOD, burden of disease; im, intramuscular; qw, once weekly; sc, subcutaneous; SD, standard deviation; tiw, three times weekly.
Median absolute change in burden of disease (BOD) in each tr atment groupFigure 1
Median absolute change in burden of disease (BOD) 
in each treatment group. IFN, interferon; im, intramuscu-
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were not possible, as only seven (2.5%) patients devel-
oped NAbs in the IFN beta-1a, 30 mcg im qw, treatment
group. Patients receiving IFN beta-1a, 30 mcg im qw,
were, therefore, treated as a single group. Median percent-
age changes in BOD in the IFN beta-1a, 44 mcg sc tiw,
NAb+ patients, IFN beta-1a, 44 mcg sc tiw, NAb- patients
and IFN beta-1a, 30 mcg im qw, patients were -0.8, -8.0
and -0.6, respectively. Absolute BOD changes were -46.2,
-254.6 and -19.0, respectively. There was no evidence of a
significant difference in percentage change in BOD from
baseline to week 48 between NAb+ patients receiving IFN
beta-1a, 44 mcg sc tiw, and those receiving IFN beta-1a, 30
mcg im qw (AMTD: 0.5%; SE: 3.9%; p = 0.583; Figure 4).
The AMTD in percentage change in BOD from baseline to
week 48 significantly favoured NAb- patients in the IFN
beta-1a, 44 mcg sc tiw, group over the IFN beta-1a, 30 mcg
im qw, group (-6.6%; SE: 2.8%; p < 0.0001).
A correlation was seen between the change in BOD from
baseline to week 48 and change in CUA from baseline to
week 24 within the IFN beta-1a, 44 mcg sc tiw, treatment
group (r = 0.385; p < 0.0001 for absolute and percentage
changes) and the IFN beta-1a, 30 mcg im qw, treatment
group (r = 0.179; p < 0.01 for absolute and percentage
changes), respectively.
Discussion and conclusion
In the current post-hoc analysis, patients with RRMS who
were treated with IFN beta-1a, 44 mcg sc tiw, had a greater
reduction in T2 BOD after 48 weeks than those given IFN
beta-1a, 30 mcg im qw. This finding is consistent with
other clinical and MRI outcome measures in the prospec-
tive EVIDENCE study. Previous prospectively defined
analyses showed that patients receiving IFN beta-1a, 44
mcg sc tiw, also had a reduced likelihood of relapse and
had significant reductions in CUA and T2 active lesions
compared with those randomized to IFN beta-1a, 30 mcg
im qw [1-3].
In general, the impact of both IFNs on suppressing Gd-
enhancing lesions on MRI is seen quite early, within the
Distribution of absolute change in burden of disease (BOD) from baseline to week 48 in the two treatment groupsFigure 2
Distribution of absolute change in burden of disease (BOD) from baseline to week 48 in the two treatment 
groups. For presentation purposes, two patients receiving interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times 
weekly (tiw), were removed from this plot; one patient had an extreme increase from baseline value of 56868.5 mm3 and 
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sidered reasonable to compare the overall change in T2
BOD for a relatively short duration of observation. Fur-
thermore, from previous experience, looking at BOD dif-
ferences over 12 months maximizes the group change
over the 'noise' created by individual variability. For com-
pleteness, the data are presented as a histogram to show
the spread of the response for both therapies. In this way
it can be seen that both therapies can be associated with a
stable MRI outcome or a worsening MRI outcome.
The distribution of absolute and percentage changes in
BOD (Figures 2 and 3) in the current analysis indicates
that patients in both treatment groups benefited from
treatment with IFN beta-1a, but 14% more patients in the
IFN beta-1a, 44 mcg sc tiw, treatment group had a stable
or improved BOD compared with those treated with IFN
beta-1a, 30 mcg im qw. In this 48-week analysis, there was
an insufficient number of patients who had a clinical pro-
gression in EDSS to explore this relationship further.
A new formulation of IFN beta-1a, 44 mcg sc tiw, has been
developed and is currently being studied in a large-scale,
Phase III, clinical trial (protocol 25632). Initial data indi-
cate that this new formulation has a reduced immuno-
genic potential, which should reduce the likelihood of
NAb development [7].
It is unclear how much NAbs affect clinical efficacy. NAbs
take time to develop and patients with NAbs at 48 weeks
may not have had NAbs during most of the preceding
time. Likewise, some patients who had developed NAbs
earlier may have lost them by week 48. Although some
studies suggest that treatment success rates may be cur-
tailed by the development of high titres of persistent NAbs
in a minority of patients following long-term treatment
with IFN beta [8-10], other studies have shown that the
clinical efficacy of IFN beta is the same in patients who are
NAb+ as in those who are NAb- [1,2,11]. However, the
studies that did not show an effect of NAbs were less than
2 years in duration, and thus may not have been of suffi-
cient duration to show an effect of NAbs on clinical out-
comes. In the current analysis, sample sizes were not large
enough to allow a direct comparison between NAb+
patients in each treatment group. Still, a comparison of
patients receiving IFN beta-1a, 44 mcg sc tiw, who devel-
oped NAbs, with all patients receiving IFN beta-1a, 30
mcg im qw (irrespective of NAb status), suggested that
NAb+ patients in the IFN beta-1a, 44 mcg sc tiw, treatment
group had a similar reduction in T2 BOD to the overall
Distribution of percentage change in burden of disease (BOD) from baseline to week 48 in the two treatment groupsFigure 3
Distribution of percentage change in burden of disease (BOD) from baseline to week 48 in the two treatment 
groups. For presentation purposes, two patients were removed from this plot because they had extreme percentage changes 
in BOD from baseline to week 48; one patient receiving interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times 
weekly (tiw), had an increase of 431% from baseline and the other patient receiving IFN beta-1a, 30 mcg intramuscularly (im) 
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words, patients with NAbs who receive high-dose, high-
frequency IFN beta still gain similar treatment benefits as
those, regardless of NAb status, who receive low-dose,
low-frequency IFN beta. This means that, although effi-
cacy may be attenuated with NAbs, therapeutic effect is
still provided by IFN beta-1a, 44 mcg sc tiw, on BOD sup-
pression. At week 48, a similar number of T2 active lesions
was seen in NAb+ patients in the IFN beta-1a, 44 mcg sc
tiw, treatment group (mean 1.6 lesions/patient/scan) as
overall (NAb+ and NAb-) in the IFN beta-1a, 30 mcg im
qw, treatment group (mean 1.4 lesions/patient/scan).
However, the reduction in BOD was smaller in the IFN
beta-1a, 44 mcg sc tiw, NAb+ group than in the IFN beta-
1a, 44 mcg sc tiw, NAb- group at 48 weeks. This may sug-
gest that MRI is more sensitive than clinical outcomes in
showing an early effect of NAbs on efficacy.
This study is probably too short to address adequately a
delayed impact of NAbs on MRI outcomes. To some
degree, this has been assessed in the PRISMS (Prevention
of Relapses and disability by Interferon beta-1a Subcuta-
neously in Multiple Sclerosis) study, in which results at 48
months showed an increase in BOD in the NAb+ group of
17.6% and a decrease of 8.5% in the NAb- group (p <
0.001) [12].
Interestingly, in the present study there was no apparent
impact of NAbs on relapse outcomes at week 48. Thus,
these MRI data indicate only a partial impact of NAbs on
efficacy outcomes at this time.
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